The future oral GLP-1 receptor agonists, incretin dual agonists, triple agonists, and other new oral metabolic products will become popular only if they prove themselves capable of producing sustained results in obesity disease, type 2 diabetes, hypertension, dyslipidemia, cardiovascular risks, and metabolic syndromes through their effectiveness and safety
Adjust dosages to match your goals
On the other hand, IAP supplementation improved metabolic syndrome in mice and prevented LPS uptake via chylomicrons, leading to improved lipid profiles and liver steatosis scores (63)
Those are not marginal differences
This hormone helps regulate your appetite, blood sugar (glucose) levels, insulin release, and digestion